Skip to main content
. 2016 Feb 3;7:10637. doi: 10.1038/ncomms10637

Figure 4. Viral delivery of TLX shRNA inhibits GSC-initiated tumour formation in vivo in a xenograft mouse model.

Figure 4

(a) Schematic of the experimental design, including GSC transplantation, viral treatment and xenogen imaging of xenografted tumours. (b) RT–PCR analysis showing TLX knockdown in vivo. N=3, **P<0.01 by Student's t-test. Error bars are s.e. of the mean. (c) Xenogen images of brain tumours in NSG mice treated with virus expressing scrambled control (SC) or TLX shRNA (shTLX). The scale for bioluminescence intensity is shown on the right. (d). Quantification of the bioluminescence intensity of tumours treated with scrambled control (SC) or TLX shRNA (shTLX) in the brains of engrafted NSG mice. N=6, **P<0.01 by Student's t-test. Error bars are s.e. of the mean. (e) Survival curves of PBT003-engrafted NSG mice treated with virus expressing either scrambled control (SC) or TLX shRNA (shTLX). X axis represents days after viral injection. N=10 for each treatment group. P<0.05 by log-rank test. (f) H&E staining of brain tumour tissues derived from transplanted PBT003 cells in NSG mice treated with scrambled control (SC) or TLX shRNA (shTLX). Scale bar, 1 mm. (g) Xenogen images of NSG mice survived over 200 days after treatment with virus expressing TLX shRNA (shTLX). (h) H&E staining showing typical tumour infiltration characteristics of glioblastoma. Scale bar, 50 μm. wk, week.